Compare NLOP & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | MDWD |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 193.3M |
| IPO Year | 2022 | 2013 |
| Metric | NLOP | MDWD |
|---|---|---|
| Price | $14.65 | $15.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 188.3K | 65.7K |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | ★ 45.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,915,000.00 | N/A |
| Revenue This Year | N/A | $48.88 |
| Revenue Next Year | N/A | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.76 | $14.14 |
| 52 Week High | $34.53 | $22.51 |
| Indicator | NLOP | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 31.36 |
| Support Level | $13.71 | N/A |
| Resistance Level | $14.70 | $18.58 |
| Average True Range (ATR) | 0.38 | 0.59 |
| MACD | 0.30 | -0.15 |
| Stochastic Oscillator | 62.16 | 10.15 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.